11月7日 - ** 药物开发商MiNK TherapeuticsINKT.O的股价盘前上涨2%至13.93美元
** 该公司称其实验性细胞疗法agenT-797对其他疗法无效的晚期癌症患者有持久疗效
** INKT称，单独或与现有免疫疗法药物一起接受agenT-797治疗的患者的中位生存期约为23个月
** 一些难以治愈的癌症（包括睾丸癌、胸腺瘤和胃癌）患者的病情在两年多的时间里得到了控制。
** 医生说，一名转移性睾丸癌患者在接受联合疗法后，病情得到了长达两年多的完全缓解 - INKT
** 其他不同癌症患者的肿瘤也出现了缩小或长期停止生长--共同社
** 截至上次收盘，股价累计上涨 96
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.